



Market Announcement

5 August 2019

Opthea Limited (ASX: OPT) – Trading Halt

Description

The securities of Opthea Limited ('OPT') will be placed in trading halt at the request of OPT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 7 August 2019 or when the announcement is released to the market.

Issued by

Cheng Tang

Senior Adviser, Listings Compliance (Melbourne)



5 August 2019

Cheng Tang
ASX Listings Compliance Advisor
ASX Compliance Pty Ltd
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By email: cheng.tang@asx.com.au
tradinghaltsmelbourne@asx.com.au

Dear Cheng

Opthea Limited (ASX: OPT)

Request for Trading Halt

Pursuant to Listing Rule 17.1, Opthea Limited (ACN 006 340 567) (**Opthea**) requests an immediate trading halt in all of its quoted securities (ASX Code: OPT), pending the release of an announcement in relation to the results of Opthea's wet AMD phase 2b clinical trial of OPT-302 (**Clinical Trial**).

Opthea requests that the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to the results of the Clinical Trial or prior to the commencement of trading on Wednesday, 7 August 2019.

Opthea is not aware of any reason why the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read "Mike Tonroe", followed by a horizontal line.

Mike Tonroe
Company Secretary